眼科 ›› 2021, Vol. 30 ›› Issue (4): 295-299.doi: 10.13281/j.cnki.issn.1004-4469.2021.04.009

• 论著 • 上一篇    下一篇

眼内淋巴瘤12例临床病理分析

张旭  顼晓琳  李彬  彭晓燕  高飞  张志豹   

  1. 首都医科大学附属北京同仁医院  北京同仁眼科中心  北京市眼科研究所  眼科学与视觉科学北京市重点实验室 100005

  • 收稿日期:2021-03-18 出版日期:2021-07-25 发布日期:2021-07-22

Clinicopathological analysis of 12 cases of intraocular lymphoma

Zhang Xu, Xu Xiaolin, Li Bin, Peng Xiaoyan, Gao Fei, Zhang Zhibao   

  1. Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University; Beijing Key Laboratory of Ophthalmology and Visual Science, Beijing 100005, China

  • Received:2021-03-18 Online:2021-07-25 Published:2021-07-22

摘要: 目的 探讨眼内淋巴瘤的临床病理特点及预后。设计 回顾性病例系列。研究对象 2012-2019年眼球摘除的眼内淋巴瘤患者12例。方法 回顾患者病历资料,分析其临床特点、组织病理学形态以及预后。主要指标 肿瘤部位、组织病理学分型、患者生存预后。结果 12例中男性7例。平均年龄(58.2±10.9)岁。均无其他部位淋巴瘤病史。11例表现为视力下降。平均病程(12.7±10.3)个月。发病部位以脉络膜最多见(9/12),其中同时累及视网膜者1例,同时累及虹膜睫状体者6例;12例中仅位于虹膜睫状体者1例,仅位于视网膜者2例。原发脉络膜部位淋巴瘤以弥漫性大B细胞淋巴瘤(DLBCL)多见(5/9),其次为黏膜相关淋巴组织边缘区B细胞淋巴瘤(MALT)(3/9)。1例原发虹膜睫状体及2例原发视网膜的淋巴瘤均为DLBCL。发生肿瘤眼球外扩散者4例,其中3例为MALT,1例为套细胞淋巴瘤(MCL)。2例发生中枢神经转移者均为DLBCL。随访11~99个月。所有DLBCL患者眼球摘除后均应用甲氨蝶呤全身化疗,肿瘤位于脉络膜及虹膜睫状体的6例患者均存活,2例肿瘤仅位于视网膜者1例死亡;3例脉络膜MALT患者术后均未采取全身化疗,目前均存活。中枢神经转移的2例DLBCL患者1例存活,1例死亡。结论 眼内淋巴瘤中脉络膜淋巴瘤多见。组织病理以DLBCL为主,其次为MALT。脉络膜DLBCL化疗后生存预后较好;脉络膜MALT易发生球外扩散,生存预后较好。视网膜淋巴瘤均为DLBCL,生存预后不佳。(眼科, 2021, 30: 295-299)


关键词:  , 眼内淋巴瘤, 弥漫性大B 细胞淋巴瘤, 黏膜相关淋巴组织边缘区B细胞淋巴瘤

Abstract: Objective To investigate the clinicopathological features and prognosis of intraocular lymphoma. Design Retrospective case series. Participants 12 cases of enucleation patients with intraocular lymphoma diagnosed from 2012 to 2019. Methods Clinical features, histopathological morphology and prognosis in medical records were reviewed. Main Outcome Measures Tumor site, pathological classification and prognosis. Results There were 7 males in 12 cases. Mean age was 58.2±10.9 years. None of the patients had a history of lymphoma in other parts of the body. The most common presentation was visual acuity loss (11/12), with a mean course of 12.6±10.3 months. The most common site of intraocular lymphoma was choroid (9/12), in which the retina was involved in 1 case (1/9) , iris and ciliary body were involved in 6 cases (6/9). Only 1 case (1/12) was located in both the ciliary body and the iris. Only the retina involved was found in 2 cases (2/12). The pathologic classification of primary choroidal lymphoma was mainly diffuse large B-cell lymphoma (DLBCL) (5/9), followed by mucosa-associated lymphoid tissue marginal B-cell lymphoma (MALT) (3/9). 1 case of primary iridociliary body lymphoma was DLBCL. 2 cases of primary retinal lymphoma were DLBCL. Extraocular diffusion occurred in 4 patients, 3 with MALT and 1 with mantle cell lymphoma (MCL). Both of the 2 patients with central nervous metastasis were DLBCL. All cases were followed up for 11-99 months. All the DLBCL patients received systemic chemotherapy with methotrexate drug after enucleation. All the 6 patients with tumors located in the choroid and iridociliary body were survived, and 1 of the 2 patients with tumors located only in the retina died and 1 was lost to follow-up. None of the 3 MALT patients with tumors located in choroid received systemic chemotherapy, and all of them have survived without disease at present. Of the 2 DLBCL patients with central nerve metastasis, 1 patient with whole uveal and retinal involvement survived after systemic chemotherapy, while 1 patient with retinal involvement only died after chemotherapy. Conclusion Choroidal lymphoma was the most common intraocular lymphoma. DLBCL was the most common pathological type, followed by MALT.  The survival prognosis of choroidal DLBCL patients after systemic chemotherapy was good. Choroidal MALT patients are prone to extraocular metastasis, and the survival prognosis is good despite no postoperative chemotherapy. All retinal lymphomas are DLBCL with poor survival and prognosis. (Ophthalmol CHN, 2021, 30: 295-299)


Key words: intraocular lymphoma, diffuse large B-cell lymphoma, mucosa-associated lymphoid tissue marginal B-cell lymphoma